https://orcid.org/0000-0002-5612-0437
References
- World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018.
- Li L, Yao S, Zou Z, et al. Analysis on the effect evaluation of the global fund tuberculosis project on MDR-TB control in the pilot city of Anhui Province. Chin J Anti-Tuberc. 2017;39(7):728–731.
- Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–2170. doi:10.1056/NEJMoa110878922670902
- Muchena G, Shambira G, Masuka N, et al. Determinants of multidrug resistance among previously treated tuberculosis patients in Zimbabwe, 2014. Int J Tuberc Lung Dis. 2017;21(11):1167–1172. doi:10.5588/ijtld.16.082629037298
- Semunigus T, Tessema B, Eshetie S, et al. Smear positive pulmonary tuberculosis and associated factors among homeless individuals in Dessie and Debre Birhan towns, Northeast Ethiopia. Ann Clin Microbiol Antimicrob. 2016;15(1):50. doi:10.1186/s12941-016-0165-x27581729
- Shariff NM, Shah SA, Kamaludin F. Previous treatment, sputum-smear nonconversion, and suburban living: the risk factors of multidrug-resistant tuberculosis among Malaysians. Int J Mycobacteriol. 2016;5(1):51–58. doi:10.1016/j.ijmyco.2015.11.00126927990
- Lv X, Lu X, Shi X, et al. Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian, China. J Int Med Res. 2017;45(6):1779–1786.28345426
- Luo D, Zhao J, Lin M, et al. Drug resistance in newly presenting and previously treated tuberculosis patients in Guangxi Province, People’s Republic of China. Asia Pac J Public Health. 2017;29(4):296–303.28397531
- Derseh D, Moges F, Tessema B. Smear positive pulmonary tuberculosis and associated risk factors among tuberculosis suspects attending spiritual holy water sites in Northwest Ethiopia. BMC Infect Dis. 2017;17(1):100. doi:10.1186/s12879-017-2211-528125981
- Sinha P, Srivastava GN, Gupta A, et al. Association of risk factors and drug resistance pattern in tuberculosis patients in North India. J Glob Infect Dis. 2017;9(4):139–145. doi:10.4103/jgid.jgid_167_1629302148
- Khan MS, Hutchison C, Coker RJ. Risk factors that may be driving the emergence of drug resistance in tuberculosis patients treated in Yangon, Myanmar. PLoS One. 2017;12(6):e0177999. doi:10.1371/journal.pone.017799928614357
- Worku J, Marjan G, Leila S, et al. Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: systematic review and meta-analysis. Rev Soc Bras Med Trop. 2017;50(3):287–295. doi:10.1590/0037-8682-0002-201728700044
- Stosic M, Vukovic D, Babic D, et al. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study. BMC Public Health. 2018;18(1):1114. doi:10.1186/s12889-018-6021-530208864
- Mesfin EA, Beyene D, Tesfaye A, et al. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. PLoS One. 2018;13(6):e0197737. doi:10.1371/journal.pone.019773729864118
- Yu S, Mei X, Yan X, et al. Case-control study on risk factors of multidrug-resistant tuberculosis in Anhui Province. J Dis Control. 2016;20(10):1026–1028.
- World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis. 4th ed. Geneva: World Health Organization; 2009.
- World Health Organization. Guidelines for Drug Susceptibility Testing for Second-Line Anti-Tuberculosis Drugs for Dots-Plus. Geneva, Switzerland: WHO; 2001.
- World Health Organization. Global Tuberculosis Report 2017. Geneva: World Health Organization; 2017.
- Van Rie A, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet. 2000;356(9223):22–25. doi:10.1016/S0140-6736(00)02429-610892760
- Chinese Medical Association Respiratory Diseases Branch. Guidelines for the diagnosis and treatment of adult adult community acquired pneumonia (2016 edition). Chin J Tuberc Res Dis. 2016;39(4):253–279.
- Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother. 2014;58(1):364–369. doi:10.1128/AAC.01228-1324165186